Diazoxide in the treatment of schizophrenia: Novel application of potassium channel openers in the treatment of schizophrenia

Journal of Clinical Pharmacy and Therapeutics

Volumn 27, Issue 6, 2002, Pages 453-459

  Akhondzadeh, Shahin ^a,b   Mojtahedzadeh, V ^a   Mirsepassi, G R ^a   Moin, M ^a   Amini Nooshabadi, H ^a   Kamalipour, A ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Institute of Medicinal Plants Iran   (Iran)

Author keywords

Diazoxide; Potassium channels; Schizophrenia

Indexed keywords

ADENOSINE TRIPHOSPHATE; BENZOTHIADIAZINE DERIVATIVE; DIAZOXIDE; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; POTASSIUM CHANNEL STIMULATING AGENT; THIAZIDE DIURETIC AGENT;

ADJUVANT THERAPY; ADULT; ARTICLE; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; HYPERPOLARIZATION; MALE; MENTAL DISEASE; METABOLISM; NERVOUS SYSTEM; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SUICIDE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; DIAZOXIDE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HALOPERIDOL; HUMANS; MALE; POTASSIUM CHANNELS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0036458709     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.2002.00445.x     Document Type: Article

References (29)

1. Jablensky A, Sartorius N, Ernberg G. (1991) Schizophrenia: Manifestation, incidence and course in different cultures. A World Health Organization ten-country study. Psychological Medicine, 20(Suppl.), 1-97.
2. Wright I, Woodruff P. (1995) Aetiology of schizophrenia. CNS Drugs, 3, 126-144.
3. Akhondzadeh S. (2001) The 5-HT hypothesis of schizophrenia. IDrugs, 4, 295-300.
4. Mohammadi MR, Akhondzadeh S. (2001) Schizophrenia: Etiology and pharmacotherapy. IDrugs, 4, 1167-1172.
5. Arndt S, Allinger RJ, Anderson NC. (1991) The distinction of positive and negative symptoms. The failure of a two dimensional model. British Journal of Psychiatry, 158, 317-322.
6. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th Edn) (DSM IV). American Psychiatric Press, Washington, DC, USA.
7. Heyman I, Murray RM. (1992) Schizophrenia and neurodevelopment. Journal of Royal Col. Physicians London, 26, 143-146.
8. Darlsson A, Waters N, Carlson ML. (1999) Neuro-transmitter interactions in schizophrenia-therapeutic implications. Biological Psychiatry, 15, 1388-1395.
9. Snyder S. (1976) The dopamine hypothesis in schizophrenia: Focus on the dopamine receptor. American Journal of Psychiatry, 133, 197-202.
10. Angrist B, Rotrosen J, Gershon S. (1980) Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia. Psychopharmacology, 72, 17-19.
11. Seiden L, Sabol K. (1993) Amphetamine: Effects on catecholamine systems and behavior. Annals of Review in Pharmacology and Toxicology, 32, 639-677.
12. Owen F, Simpson M. (1994) The neurochemistry of schizophrenia. Molecular Cell Biology Human Disease, 4,133-159.
13. Akhondzadeh S. (1998) The glutamate hypothesis of schizophrenia. Journal of Clinical Pharmacy and Therapeutics, 23, 243-246.
14. Noorbala AA, Akhondzadeh S, Davari-Ashtiani R, Amini-Nooshabadi H. (1999) Piracetam in the treatment of schizophrenia: Implications for the glutamate hypothesis of schizophrenia. Journal of Clinical Pharmacy and Therapeutics, 24, 369-374.
15. Akhondzadeh S, Mohammadi MA, Amini-Noosha-badi H, Davari-Ashtiani R. (1999) Cyproheptadine in treatment of chronic schizophrenia: A double-blind, placebo-controlled study. Journal of Clinical Pharmacy and Therapeutics, 24, 49-52.
16. Akhondzadeh S, Shasavand E, Jamilian HR, Shabestari O, Kamalipour A. (2000) Dipyridamole in the treatment of schizophrenia: Adenosine-dopamine receptor interactions. Journal of Clinical Pharmacy and Therapeutics, 25, 131-137.
17. Marder SR. (2000) Newer antipsychotics. Current Opinion in Psychiatry, 13, 11-14.
18. Lin YJ, Greif GJ, Freedman JE. (1993) Multiple sulfonylurea-sensitive potassium channels: A novel subtype modulated by dopamine. Molecular Pharmacology, 44, 907-910.
19. Allen JW, Etcheberrigaray R. (1998) Potassium channels in neuropsychatric disorders. CNS Drugs, 10, 61-82.
20. Pongs O. (1992) Molecular biology of voltage-dependent potassium channels. Physiological Review, 72(Suppl.), 69-88.
21. Freedman JE, Lin YJ. (1996) ATP-sensitive potassium channels: Diverse functions in the central nervous system. Neuroscientist, 2, 145-152.
22. Evans JM, Taylor SG. (1994) Potassium channel activators: Pharmacological methods, models, and structure-activity relationships. Progress in Medical Chemistry, 31, 411-416.
23. Edwards G, Weston AH. (1995) Pharmacology of the potassium channel openers. Cardiovascular Drugs Therapeutics, 9, 185-193.
24. Sturgess NC, Kozlowski RZ, Carrington CA. (1988) Effects of sulphonylureas and diazoxide on insulin secretion and nucleotide-sensitive channels in an insulin-secreting cell line. British Journal of Pharmacology, 95, 83-94.
25. Kay SR, Fiszbein A, Opler LA. (1987) The positive and negative syndrome scale for schizophrenia. Schizophrenia Bulletin, 13, 261-276.
26. Anderson NC. (2000) Schizophrenia: The fundamental questions. Brain Research Reviews, 31, 106-112.
27. Anderson NC, Olsen SA. (1982) Negative vs. positive schizophrenia: Definition and validation. Archives of General Psychiatry, 39, 789-794.
28. Richelson E. (1999) Receptor pharmacology of neuroleptics: Relation to clinical effects. Journal of Clinical Psychiatry, 60, 5-14.
29. Kendler KS, Diehl SR. (1993) The genetics of schizophrenia: A current genetic-epidemiologic perspective. Schizophrenia Bulletin, 19, 261-285.